Advancing Nanomedicine Through Particle Technology
Funder
National Health and Medical Research Council
Funding Amount
$876,005.00
Summary
This proposal will support the development of advanced particle systems to improve the delivery of medicines in neurological diseases, HIV, diabetes and cancer. It will provide important insights for particle-based therapeutic delivery that are expected to underpin progress on nanotechnology in the areas of biology and medicine. These developments in nanotechnology-enabled medicines towards commercialisation will ultimately improve the health and quality of life of Australians.
Identifying Drug Targets In Microbial Pathogens Using Metabolomics
Funder
National Health and Medical Research Council
Funding Amount
$763,409.00
Summary
Infectious diseases such as malaria, leishmaniasis and tuberculosis cause enormous morbidity and mortality worldwide. This proposal will utilize advanced analytical and genetic approaches to study the metabolism of the respective protozoan and bacteria agents as well as the associated host responses. These approaches will be used to develop novel therapeutic approaches and new analytical tools that can be applied to other infectious diseases
Relaxin family peptides are small proteins that have numerous essential biological roles in the vascular system, brain and gut. The hormone relaxin is currently in Phase III clinical trials to treat heart failure and the other peptides show great potential as drugs to treat diseases including mental illnesses and obesity. My research focuses on developing drugs targeting the receptors for these important peptide systems and understanding how these drugs can be best used therapeutically
Understanding Australia’s Drug Use: Prescription Psychotropics, Recreational Drugs And Novel Emerging Psychoactive Substances
Funder
National Health and Medical Research Council
Funding Amount
$763,409.00
Summary
Australians are consuming record levels of drugs that affect their mood and behaviour, both prescribed and illicit. They are also consuming an increasing array of novel synthetic drugs, the effects of which are largely unknown. Professor Iain McGregor engages in innovative research that examines the drugs we take, their effects on the brain, and their risks and benefits. His team also develops new medications that may become future treatments for anxiety, depression and addictions.
Small Molecule Therapeutics: From Infectious And Parasitic Diseases To Cancers
Funder
National Health and Medical Research Council
Funding Amount
$763,845.00
Summary
I will lead a team of medicinal chemists to discover better treatments of diseases focused in two major domains. On one hand, I will discover new drugs to treat certain parasitic diseases such as Sleeping Sickness, Chagas disease and malaria, all caused by protozoal parasites. On the other hand, I will discover new drugs to treat certain cancers, in particular acute myeloid leukemia and Burkitt’s lymphoma, caused by dysfunction of certain types of enzymes called histone acetyltransferases.
Prof Khachigian is a vascular cell and molecular biologist elucidating fundamental transcriptional mechanisms that lead to the inappropriate expression of harmful genes in vascular cells. Exploiting this science, I am also a “translational” researcher who has pioneered the development of novel strategies targeting key regulatory genes to combat angiogenesis-dependent cancers, and potentially other common vascular disorders such as post-angioplasty restenosis, bypass graft stenosis, ocular neovas ....Prof Khachigian is a vascular cell and molecular biologist elucidating fundamental transcriptional mechanisms that lead to the inappropriate expression of harmful genes in vascular cells. Exploiting this science, I am also a “translational” researcher who has pioneered the development of novel strategies targeting key regulatory genes to combat angiogenesis-dependent cancers, and potentially other common vascular disorders such as post-angioplasty restenosis, bypass graft stenosis, ocular neovascularisation and rheumatoid arthritis.Read moreRead less
Fellowship Application, Ed Stanley: Pluripotent Stem Cells & Medical Research
Funder
National Health and Medical Research Council
Funding Amount
$638,517.00
Summary
Human Pluripotent Stem Cells are immortal cells that have the ability to turn into any of the cell types found in the body. This means that it is now possible to generate a variety of human cell types in the laboratory, to study how they work, and to find out what goes wrong in different diseases. In this context, the overall aim of my research is to develop pluripotent stem cells for the study of human disease and generate tools that will enable others to use these cells in their own research.
The genetic material is packaged in the cell nucleus with histone proteins. Modifications of histones determine if a particular area of the genome is active or repressed. We are investigating the roles of a family of histone modifying proteins, the MYST proteins. Mutations in these proteins cause intellectual disability and cancer. The research program will provide knowledge that may become the basis for the development of drugs for the treatment of cancer and neurodegenerative disorders.
Prof A Suhrbier is the Group Leader of the Inflammation Biology Group at the Queensland Institute of Medical Research. The group focuses at the applied end of inflammation research and development and will be involved in the identification and development of new interventions and diagnostics for inflammatory diseases and cancer, often in collaboration with the biotech industry.
Biomedical Investigations Of Pharmacology And Pathology For Disease Treatment
Funder
National Health and Medical Research Council
Funding Amount
$863,413.00
Summary
I am an NHMRC SPRF & Director of the Molecular Pharmacology & Pathology Program consisting of 34 researchers. The breadth of our studies is diverse & continues to expand. Excitingly, we have recently obtained commercialisation support to develop our anti-tumour drug, DpC. My vision for the next 5 yrs is to direct development of these agents together with investigations of basic mechanism. These studies will be done with a team of outstanding researchers I am mentoring and an established group of ....I am an NHMRC SPRF & Director of the Molecular Pharmacology & Pathology Program consisting of 34 researchers. The breadth of our studies is diverse & continues to expand. Excitingly, we have recently obtained commercialisation support to develop our anti-tumour drug, DpC. My vision for the next 5 yrs is to direct development of these agents together with investigations of basic mechanism. These studies will be done with a team of outstanding researchers I am mentoring and an established group of experienced collaborators.Read moreRead less